Front Page
March 6, 2023
Ask an Expert: Is Mandating Treatment Necessary or Helpful?
Caleb Banta-Green, PhD, MPH, MSWDirector, UW Center for Community-Engaged Epidemiology, Education, and Research (CEDEER) Substance use-related health services are a well-researched area. Many people, however, have outdated understandings of substance use and “substance use disorder” (addiction) and also don’t know much about what truly motivates someone to seek services to reduce the harms associated with…
February 22, 2023
New ADAI Report & Virtual Tour: Overview and Perspectives of Syringe Services Programs in WA State
New ADAI Report This new report, Overview and Perspectives of Syringe Services Programs in Washington State, written by Susan Kingston of the ADAI Center for Community-Engaged Drug Education, Epidemiology and Research (CEDEER), describes how Washington State syringe services programs (SSPs) operate, the services they provide, the challenges they face, and their untapped potential. Citation: Kingston…
ADAI Lunch & Learn: Community Engaged Research with People Who Use Drugs: Lessons Learned from the READU Team (March 14, 12pm PT)
Join ADAI and presenters Jenna van Draanen, PhD, MPH and Courtney Wetterman (both of the UW School of Nursing) for our next virtual Lunch & Learn, March 14, 2023, 12-1pm PT. This presentation will cover principles and methods of community-engaged research, using an example from our research team of people with lived and living experience…
February 15, 2023
ADAI in the News: Dr. Caleb Banta-Green on Over-the-Counter Naloxone and Low-Barrier Treatment
ADAI Acting Professor Caleb Banta-Green, PhD, MPH, MSW recently talked with Scripps National News about making the opioid overdose antidote naloxone available over-the-counter (OTC). The FDA is meeting today (Feb. 15, 2023) to review the application for an OTC version of naloxone nasal spray. Though the goal of such a move would be to expand…
February 8, 2023
New from ADAI: Community Implementation of Contingency Management to Address Stimulant Use (Hartzler, 2023)
A new publication by ADAI Research Associate Professor Bryan Hartzler, PhD and colleagues reports outcomes of an interagency partnership among the Northwest ATTC, Oregon Health Authority, and Oregon Recovery and Treatment Centers, LLC. This partnership involved an intensive technical assistance project in which opioid treatment programs successfully implemented customized contingency management programming to increase stimulant abstinence…
February 6, 2023
New: How Should Policymakers Regulate the THC Content of Cannabis Products? (Opinion piece in Addiction)
Since the sale of cannabis to adults was first legalized in Colorado and Washington State in 2012, the THC content of cannabis flower has increased and so have sales of high-potency cannabis vapes, extracts, and concentrates. Increased use of higher THC cannabis products can lead to increased cannabis-related harms, including accidents, adverse psychological reactions, psychotic…
February 3, 2023
New Research: “Like it was just everyday business”: Experiences of Pharmacy Customers Requesting Naloxone or Syringes
As rates of overdoses involving opioids continue to rise in the U.S., community pharmacies are increasingly being seen as a way to provide easier and expanded access to harm reduction supplies like naloxone and non-prescription syringes (NPS). This article, co-authored by ADAI Research Associate Professor Anthony S. Floyd, PhD, looks at what customers thought of…
February 1, 2023
ADAI IS HIRING! Director of Program Operations (100% FTE, $6813-$10,219/month)
Come join an organization that is truly making a difference! The UW Addictions, Drug & Alcohol Institute (Department of Psychiatry & Behavioral Sciences, UW School of Medicine) is currently seeking a Director of Program Operations to provide oversight and direction for the various programs and projects in our institute. In this position, you’ll work closely…
January 30, 2023
High THC Policy | Final Report: Exploring Policy Solutions: Report to the WA Legislature
To address this emerging public safety challenge of increasingly available high-THC products (e.g. dabs, wax, concentrates), the WA State Health Care Authority was directed by ESSB 5092 (2021) to contract with the University of Washington’s Addictions, Drug & Alcohol Institute (ADAI) to identify areas of common ground and consensus, and develop recommendations for state policies related to cannabis concentration…
January 18, 2023
Webinar: What’s the Latest on Xylazine? (Feb 15, 12pm PT)
February 15, 2023 | 12-1pm PT | View recording Xylazine is a veterinary tranquilizer that has been found mixed with other drugs like fentanyl and heroin. Evidence indicates overdose deaths involving Xylazine have increased throughout the United States, including in the Pacific Northwest, with the largest impact occurring in the Northeast. This webinar from ADAI’s…
Previous page Next page
